Clinical trial
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in…
NCT00003906 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00003906 |
|---|---|
| Title | Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women |
| Official title | Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eli Lilly and Company Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Raloxifene, Tamoxifen |
| Enrollment | 19,747 |
| Start date | May 1, 1999 |
| Primary completion | Dec 1, 2005 |
| Completion | Aug 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 6, 2015 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: